Sector News

Seattle Genetics on a ‘great trajectory,’ looks to grow staff by 100

April 24, 2015
Life sciences
Seattle Genetics is hiring for 100 positions, Chief Operating Officer Eric Dobmeier said Thursday.
 
The Bothell-based biotech company (Nasdaq: SGEN) is looking to fill positions ranging from biostatisticians and research associates to the head of its cancer research program and vice president of marketing.
 
That growth is to keep the company, which develops cancer treatments, on track with what a Seattle Genetics spokeswoman called a “great trajectory.”
 
Hiring new people will also coincide with the company ramping up spending in coming years to support preclinical developments, clinical trial activities and continue the commercialization of its flagship product Adcetris, according to a recent filing with the Securities and Exchange Commission. Adcetris is used to treat lymphoma.
 
Seattle Genetics is also investing heavily in its pipeline. That was one factor that led to a $27 million loss in the fourth quarter last year.
 
Even after that loss, though, the company’s stock held steady. Today it is trading at about $37 per share.
 
The company will report first quarter earnings next week.
 
By Annie Zak
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.